Minerva Neurosciences, Inc (NERV) Shares Bought by Northern Trust Corp

Northern Trust Corp increased its stake in Minerva Neurosciences, Inc (NASDAQ:NERV) by 27.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 298,507 shares of the biopharmaceutical company’s stock after purchasing an additional 65,056 shares during the period. Northern Trust Corp owned approximately 0.81% of Minerva Neurosciences worth $2,641,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Citigroup Inc. boosted its stake in shares of Minerva Neurosciences by 8,842.2% during the 2nd quarter. Citigroup Inc. now owns 253,065 shares of the biopharmaceutical company’s stock worth $2,240,000 after buying an additional 250,235 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Minerva Neurosciences by 48.0% in the 2nd quarter. GSA Capital Partners LLP now owns 58,600 shares of the biopharmaceutical company’s stock valued at $519,000 after purchasing an additional 19,000 shares during the last quarter. New York State Common Retirement Fund lifted its stake in Minerva Neurosciences by 62.4% in the 2nd quarter. New York State Common Retirement Fund now owns 28,100 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 10,799 shares during the last quarter. ProShare Advisors LLC lifted its stake in Minerva Neurosciences by 1.4% in the 2nd quarter. ProShare Advisors LLC now owns 21,063 shares of the biopharmaceutical company’s stock valued at $186,000 after purchasing an additional 297 shares during the last quarter. Finally, Laurion Capital Management LP acquired a new stake in Minerva Neurosciences in the 2nd quarter valued at about $326,000. 73.76% of the stock is owned by hedge funds and other institutional investors.

NERV has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research note on Tuesday, August 22nd. Citigroup began coverage on shares of Minerva Neurosciences in a report on Friday, September 1st. They issued a “buy” rating and a $11.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Minerva Neurosciences presently has a consensus rating of “Hold” and an average target price of $13.94.

Shares of Minerva Neurosciences, Inc (NASDAQ:NERV) traded down $0.20 on Tuesday, hitting $5.85. 265,835 shares of the stock traded hands, compared to its average volume of 217,993. Minerva Neurosciences, Inc has a 12 month low of $4.80 and a 12 month high of $14.00.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. During the same quarter last year, the company earned ($0.24) EPS. research analysts predict that Minerva Neurosciences, Inc will post -1.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Minerva Neurosciences, Inc (NERV) Shares Bought by Northern Trust Corp” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/12/northern-trust-corp-buys-65056-shares-of-minerva-neurosciences-inc-nerv.html.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply